More News

Base to Base biotech podcast 74: A vision for vision, and studying pancreatic cancer

Jim Cornall -
This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell...

FDA first-ever treatment for warm autoimmune haemolytic anaemia

Jim Cornall -
Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY (nipocalimab-aahu) for the treatment...

Rhode Island launches programme to attract life science startups

Jim Cornall -
The Rhode Island Life Science Hub (RILSH) has announced the Founders Compass Program, offered in partnership with Portal Innovations...

Novel drug shows promise in an early phase heart failure trial

Jim Cornall -
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in...

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Jim Cornall -
African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to $16.5m from the...

HiRO and Differentia Biotech look to redefine clinical trial design

Jim Cornall -
At a time when biopharma R&D productivity is declining and the cost of bringing a single drug to market...

Rogue neuronal signal is at the heart of Alzheimer’s disease

admin -
New research suggests a broad range of Alzheimer’s pathologies may be orchestrated by a molecular switch called ERBB4 when...

Aficamten trial positive for patients with non-obstructive hypertrophic cardiomyopathy

Jim Cornall -
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic...

New clues about causes of severe headaches

Jim Cornall -
Inflammation, altered gene regulation, and exposure to substances in tobacco smoke may all contribute to the development of cluster...

Base to Base biotech podcast 73: Polymacrocyclic peptides and AI in drug discovery and diagnosis

Jim Cornall -
This week, our guests are chief scientific officer of Valo Health, Karin Conde-Knape, and Karsten Eastman, CEO of Sethera...

Researchers discover mechanism that helps colorectal cancer spread

Jim Cornall -
Researchers from the University of Turku in Finland and Gustave Roussy Institute in France have discovered a molecular mechanism...

Gut bacteria may communicate differently with the body in patients with Parkinson’s disease

Jim Cornall -
A new study from the University of Oulu suggests gut bacteria may send different biological signals in Parkinson’s disease....

Colospan announces positive results from intraoperative tissue assessment technology

Jim Cornall -
Colospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd., has successfully completed a feasibility study supporting the development...

New norovirus vaccine approach may help treat other RNA viruses

Jim Cornall -
On a genetic level, RNA viruses share common structural elements. The RNA of their genomes has strings, folds, and...

Base to Base biotech podcast 72: Cell-free DNA bioproduction

Jim Cornall -
This week, we have a conversation about the Flexible Automation for Scalable Health (FLASH) programme, focused on the development...

KTU chemists develop dual-action compounds to fight cancer

Jim Cornall -
Cancer patients often face more than the disease itself. Treatment is frequently complicated by infections and other health conditions,...

RSV antiviral drug receives FDA approval for phase II trial

Jim Cornall -
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir...

Research uncovers new driver of immunotherapy resistance in pancreatic cancer

Jim Cornall -
Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The...

Pilot project between BioCytics and LIDE Biotech

Jim Cornall -
BioCytics, Inc., and LIDE Biotech have formed a strategic alliance to develop advanced screening platforms and companion diagnostics for...

IASO acquires cell therapy company MediSix

Jim Cornall -
IASO Biotechnology has completed its acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering and cell therapy company. The acquisition...

Jazz Pharmaceuticals to acquire Actio Biosciences and expand rare epilepsy portfolio

Jim Cornall -
Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have entered into a definitive agreement for Jazz to acquire privately-held Actio...